MicroSectors FANG Index -3X Inverse Leveraged ETNs due January 8, 2038 Azioni (ARCA: FNGD)

Ultime notizie per MicroSectors FANG Index -3X Inverse Leveraged ETNs due January 8, 2038 (ARCA:FNGD) Azioni

MicroSectors FANG Index -3X Inverse Leveraged ETNs due January 8, 2038

<ul>
<li>Acquisition adds Franklin solution, an AI-powered cloud platform for clinical decision support in genetic diseases</li>
<li>Strengthens QIAGEN Digital Insights offering for small and mid-sized labs worldwide with easy-to-use, fast and flexible NGS data interpretation in a rapidly growing market</li>
<li>Franklin complements QCI Interpret, QCI Precision Insights and QIAGEN's leading genetic databases COSMIC and HGMD</li>
</ul>

News

QGEN

QIAGEN To Acquire GENOOX For $70M

DiaMedica Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMAC#NASDAQ">DMAC</a>) is gearing up to announce its quarterly earnings on Tuesday, 2025-05-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that DiaMedica Therapeutics will report an earnings per share (EPS) of $-0.18.
The announcement from DiaMedica Therapeutics is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company missed EPS by $0.01, leading to a 13.02% drop in the share price the following trading session.
Here's a look at DiaMedica Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.17</td>
<td>-0.15</td>
<td>-0.16</td>
<td>-0.16</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.18</td>
<td>-0.15</td>
<td>-0.13</td>
<td>-0.14</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-13.0%</td>
<td>-3.0%</td>
<td>3.0%</td>
<td>-6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747080569_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of DiaMedica Therapeutics were trading at $3.66 as of May 09. Over the last 52-week period, shares are up 28.81%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/DMAC/earnings">To track all earnings releases for DiaMedica Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

DMAC

Insights Ahead: DiaMedica Therapeutics's Quarterly Earnings

DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) affirms FY2025 Adj EPS guidance from $10.20-$11.30 to $10.20-$11.30 vs $10.89 analyst estimate..

Guidance

DaVita Affirms FY2025 Adj EPS Guidance of $10.20-$11.30 vs $10.89 Est

GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) sees Q2 sales of $275.000 million-$305.000 million vs $259.80 million analyst estimate.

GigaCloud Tech Sees Q2 Sales $275.000M-$305.000M vs $259.80M Est

Pennant Park Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNNT#NYSE">PNNT</a>) reported quarterly earnings of $0.18 per share which met the analyst consensus estimate. This is a 18.18 percent decrease over earnings of $0.22 per share from the same period last year. The company reported quarterly sales of $30.66 million which missed the analyst consensus estimate of $33.14 million by 7.48 percent. This is a 14.78 percent decrease over sales of $35.98 million the same period last year.

Earnings Misses

PNNT

Pennant Park Investment Q2 EPS $0.18, Inline, Sales $30.66M Miss $33.14M Estimate

Verrica Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRCA#NASDAQ">VRCA</a>) will release its quarterly earnings report on Tuesday, 2025-05-13. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Verrica Pharmaceuticals to report an earnings per share (EPS) of $-0.15.
The announcement from Verrica Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
In the previous earnings release, the company beat EPS by $0.06, leading to a 7.56% drop in the share price the following trading session.
Here's a look at Verrica Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.24</td>
<td>-0.37</td>
<td>-0.42</td>
<td>-0.40</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.18</td>
<td>-0.43</td>
<td>-0.31</td>
<td>-0.38</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>-44.0%</td>
<td>-7.000000000000001%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747080538_0.png" alt="eps graph" />
<h3>Market Performance of Verrica Pharmaceuticals's Stock</h3>
Shares of Verrica Pharmaceuticals were trading at $0.44 as of May 09. Over the last 52-week period, shares are down 94.64%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/VRCA/earnings">To track all earnings releases for Verrica Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VRCA

Earnings Outlook For Verrica Pharmaceuticals

OncoCyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCX#NASDAQ">OCX</a>) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17.39 percent. This is a 83.19 percent increase over losses of $(1.13) per share from the same period last year. The company reported quarterly sales of $2.32 million which beat the analyst consensus estimate of $154.50 thousand by 1.40K percent. This is a 1.22K percent increase over sales of $176.00 thousand the same period last year.

Earnings Beats

OncoCyte Q1 Adj. EPS $(0.19) Beats $(0.23) Estimate, Sales $2.32M Beat $154.50K Estimate

DaVita (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVA#NYSE">DVA</a>) reported quarterly earnings of $2.00 per share which beat the analyst consensus estimate of $1.95 by 2.56 percent. This is a 15.97 percent decrease over earnings of $2.38 per share from the same period last year. The company reported quarterly sales of $3.22 billion which beat the analyst consensus estimate of $3.21 billion by 0.53 percent. This is a 4.98 percent increase over sales of $3.07 billion the same period last year.

DaVita Q1 Adj. EPS $2.00 Beats $1.95 Estimate, Sales $3.22B Beat $3.21B Estimate

ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) raises FY2025 Adj EPS guidance from $0.95-$0.97 to $0.96-$0.98 vs $0.96 analyst estimate. Raises FY2025 sales outlook from $1.19 billion-$1.21 billion to $1.20 billion-$1.21 billion vs $1.19 billion estimate.

ZoomInfo Technologies Raises FY2025 Adj EPS Guidance from $0.95-$0.97 to $0.96-$0.98 vs $0.96 Est; Raises FY2025 Sales Guidance from $1.19B-$1.21B to $1.20B-$1.21B vs $1.19B Est

GigaCloud Tech Q1 Adj. EPS $0.83 Beats $0.52 Estimate, Sales $271.91M Beat $259.80M Estimate

ZoomInfo Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZI#NASDAQ">ZI</a>) is looking for Q2 Adj EPS of $0.22-$0.24 vs $0.22 analyst estimate. sees sales of $295.000 million-$298.000 million vs $295.30 million analyst estimate.

ZoomInfo Technologies Sees Q2 Adj EPS $0.22-$0.24 vs $0.22 Est; Sees Sales $295.000M-$298.000M vs $295.30M Est

Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.14) by 28.57 percent. This is a 38.46 percent decrease over losses of $(0.13) per share from the same period last year. The company reported quarterly sales of $20.75 million which missed the analyst consensus estimate of $27.60 million by 24.81 percent. This is a 44.76 percent decrease over sales of $37.57 million the same period last year.

BLNK

Blink Charging Q1 Adj. EPS $(0.18) Misses $(0.14) Estimate, Sales $20.75M Miss $27.60M Estimate

Hudson Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSON#NASDAQ">HSON</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-13. Here's what investors need to know before the announcement.
Analysts estimate that Hudson Global will report an earnings per share (EPS) of $0.06. 
The announcement from Hudson Global is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.11, which was followed by a 0.0% drop in the share price the next day.
Here's a look at Hudson Global's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.16</td>
<td>0</td>
<td>-0.07</td>
<td>0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.05</td>
<td>-0.13</td>
<td>0.04</td>
<td>-0.72</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747080515_0.png" alt="eps graph" />
<h3>Performance of Hudson Global Shares</h3>
Shares of Hudson Global were trading at $10.1999 as of May 09. Over the last 52-week period, shares are down 38.34%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/HSON/earnings">To track all earnings releases for Hudson Global visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

HSON

Hudson Global's Earnings: A Preview

UBS analyst Timothy Arcuri maintains Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Buy and lowers the price target from $300 to $295.

Price Target

Analyst Ratings

UBS Maintains Buy on Analog Devices, Lowers Price Target to $295

OptimizeRx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRX#NASDAQ">OPRX</a>) reported quarterly earnings of $0.08 per share which beat the analyst consensus estimate of $(0.12) by 166.67 percent. This is a 172.73 percent increase over losses of $(0.11) per share from the same period last year. The company reported quarterly sales of $21.93 million which beat the analyst consensus estimate of $18.69 million by 17.35 percent. This is a 11.37 percent increase over sales of $19.69 million the same period last year.

OPRX

OptimizeRx Q1 Adj. EPS $0.08 Beats $(0.12) Estimate, Sales $21.93M Beat $18.69M Estimate

Archer Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.28) by 39.29 percent. This is a 52.78 percent increase over losses of $(0.36) per share from the same period last year.

ACHR

Archer Aviation Q1 EPS $(0.17) Beats $(0.28) Estimate

Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 300 percent decrease over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $46.85 million which beat the analyst consensus estimate of $44.01 million by 6.46 percent. This is a 27.00 percent decrease over sales of $64.18 million the same period last year.

MRVI

Maravai LifeSciences Q1 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $46.85M Beat $44.01M Estimate

ACCESS Newswire (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ACCS#AMEX">ACCS</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-05-13. Here's what investors need to know before the announcement.
Analysts estimate that ACCESS Newswire will report an earnings per share (EPS) of $0.13. 
Investors in ACCESS Newswire are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.02, leading to a 3.14% drop in the share price on the subsequent day.
Here's a look at ACCESS Newswire's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.23</td>
<td>0.20</td>
<td>0.21</td>
<td>0.29</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.21</td>
<td>0.17</td>
<td>0.22</td>
<td>0.08</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-5.0%</td>
<td>3.0%</td>
<td>-17.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1747080473_0.png" alt="eps graph" />
<h3>Tracking ACCESS Newswire's Stock Performance</h3>
Shares of ACCESS Newswire were trading at $8.9 as of May 09. Over the last 52-week period, shares are down 10.71%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/ACCS/earnings">To track all earnings releases for ACCESS Newswire visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACCS

Preview: ACCESS Newswire's Earnings

Simon Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPG#NYSE">SPG</a>) affirms FY2025 FFO guidance from $12.40-$12.65 to $12.40-$12.65 vs $12.56 analyst estimate..

Simon Property Group Affirms FY2025 FFO Guidance of $12.40-$12.65 vs $12.56 Est

Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $(0.06) by 316.67 percent. This is a 192.86 percent increase over losses of $(0.14) per share from the same period last year. The company reported quarterly sales of $1.47 million which missed the analyst consensus estimate of $2.55 million by 42.29 percent. This is a 51.77 percent decrease over sales of $3.05 million the same period last year.

RGTI

Rigetti Computing Q1 EPS $0.13 Beats $(0.06) Estimate, Sales $1.47M Miss $2.55M Estimate

ZC SP ETN REDEEM 08/01/2038 USD 50 - Se D FNGD

Comments

MicroSectors FANG Index -3X Inverse Leveraged ETNs due January 8, 2038

Notizie

Ultime notizie per MicroSectors FANG Index -3X Inverse Leveraged ETNs due January 8, 2038 (ARCA:FNGD) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO